Global burden and economic impact of vaccine-preventable cancer mortality.

IF 2.9 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Journal of Medical Economics Pub Date : 2024-04-01 Epub Date: 2024-05-22 DOI:10.1080/13696998.2024.2350877
Goran Bencina, Edward Oliver, Anne Meiwald, Robert Hughes, Edith Morais, Georgie Weston, Karin Sundström
{"title":"Global burden and economic impact of vaccine-preventable cancer mortality.","authors":"Goran Bencina, Edward Oliver, Anne Meiwald, Robert Hughes, Edith Morais, Georgie Weston, Karin Sundström","doi":"10.1080/13696998.2024.2350877","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Infections are responsible for approximately 13% of cancer cases worldwide and many of these infections can be prevented by vaccination. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the most common infections that cause cancer deaths globally, despite effective prophylactic vaccines being available. This analysis aims to estimate the global burden and economic impact of vaccine-preventable cancer mortality across World Health Organization (WHO) regions.</p><p><strong>Methods: </strong>The number of deaths and years of life lost (YLL) due to five different vaccine-preventable cancer forms (oral cavity, liver, laryngeal, cervical, and oropharyngeal cancer) in each of the WHO regions (African, Eastern Mediterranean, European, the Americas, South-East Asia Pacific, and Western Pacific) were obtained from the Institute for Health Metrics Evaluation global burden of disease dataset. Vaccine-preventable mortality was estimated considering the fraction attributable to infection, to estimate the number of deaths and YLL potentially preventable through vaccination. Data from the World Bank on GDP per capita were used to estimate the value of YLL (VYLL). The robustness of these results was explored with sensitivity analysis. Given that several Epstein-Barr virus (EBV) vaccines are in development, but not yet available, the impact of a potential vaccine for EBV was evaluated in a scenario analysis.</p><p><strong>Results: </strong>In 2019, there were 465,740 potentially vaccine-preventable cancer deaths and 14,171,397 YLL across all WHO regions. The estimated economic impact due to this mortality was $106.3 billion globally. The sensitivity analysis calculated a range of 403,025-582,773 deaths and a range in productivity cost of $78.8-129.0 billion. In the scenario analysis EBV-related cancer mortality increased the global burden by 159,723 deaths and $32.4 billion.</p><p><strong>Conclusion: </strong>Overall, the findings from this analysis illustrate the high economic impact of premature cancer mortality that could be potentially preventable by vaccination which may assist decision-makers in allocating limited resources among competing priorities. Improved implementation and increased vaccination coverage of HPV and HBV should be prioritized to decrease this burden.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"9-19"},"PeriodicalIF":2.9000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13696998.2024.2350877","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Infections are responsible for approximately 13% of cancer cases worldwide and many of these infections can be prevented by vaccination. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the most common infections that cause cancer deaths globally, despite effective prophylactic vaccines being available. This analysis aims to estimate the global burden and economic impact of vaccine-preventable cancer mortality across World Health Organization (WHO) regions.

Methods: The number of deaths and years of life lost (YLL) due to five different vaccine-preventable cancer forms (oral cavity, liver, laryngeal, cervical, and oropharyngeal cancer) in each of the WHO regions (African, Eastern Mediterranean, European, the Americas, South-East Asia Pacific, and Western Pacific) were obtained from the Institute for Health Metrics Evaluation global burden of disease dataset. Vaccine-preventable mortality was estimated considering the fraction attributable to infection, to estimate the number of deaths and YLL potentially preventable through vaccination. Data from the World Bank on GDP per capita were used to estimate the value of YLL (VYLL). The robustness of these results was explored with sensitivity analysis. Given that several Epstein-Barr virus (EBV) vaccines are in development, but not yet available, the impact of a potential vaccine for EBV was evaluated in a scenario analysis.

Results: In 2019, there were 465,740 potentially vaccine-preventable cancer deaths and 14,171,397 YLL across all WHO regions. The estimated economic impact due to this mortality was $106.3 billion globally. The sensitivity analysis calculated a range of 403,025-582,773 deaths and a range in productivity cost of $78.8-129.0 billion. In the scenario analysis EBV-related cancer mortality increased the global burden by 159,723 deaths and $32.4 billion.

Conclusion: Overall, the findings from this analysis illustrate the high economic impact of premature cancer mortality that could be potentially preventable by vaccination which may assist decision-makers in allocating limited resources among competing priorities. Improved implementation and increased vaccination coverage of HPV and HBV should be prioritized to decrease this burden.

可通过疫苗预防的癌症死亡率对全球造成的负担和经济影响。
背景全球约有 13% 的癌症病例是由感染引起的,其中许多感染是可以通过接种疫苗来预防的。人类乳头瘤病毒(HPV)和乙型肝炎病毒(HBV)是导致全球癌症死亡的最常见感染之一,尽管目前已有有效的预防疫苗。本分析旨在估算世界卫生组织(WHO)各地区可通过疫苗预防的癌症死亡率对全球造成的负担和经济影响。方法从卫生计量评价研究所的全球疾病负担数据集中获取世界卫生组织各地区(非洲、东地中海、欧洲、美洲、东南亚太平洋和西太平洋)因五种不同的可通过疫苗预防的癌症形式(口腔癌、肝癌、喉癌、宫颈癌和口咽癌)造成的死亡人数和生命损失年数(YLL)。在估算可通过疫苗预防的死亡率时,考虑了可归因于感染的部分,以估算可通过疫苗接种潜在预防的死亡人数和YLL。世界银行的人均 GDP 数据用于估算 YLL 的价值 (VYLL)。通过敏感性分析探讨了这些结果的稳健性。鉴于有几种 Epstein-Barr 病毒 (EBV) 疫苗正在研发中,但尚未上市,因此在情景分析中评估了 EBV 潜在疫苗的影响。结果2019 年,世界卫生组织所有地区共有 465,740 例可通过疫苗预防的癌症死亡病例和 14,171,397 例 YLL。据估计,这一死亡率对全球造成的经济影响为 1,063 亿美元。敏感性分析计算出的死亡人数范围为 403,025-582,773 人,生产成本范围为 788 亿-1,290 亿美元。在情景分析中,与 EBV 相关的癌症死亡率使全球负担增加了 159,723 例死亡和 324 亿美元。结论总体而言,本分析的结果表明,接种疫苗有可能预防癌症过早死亡,从而对经济产生巨大影响,这可能有助于决策者在相互竞争的优先事项中分配有限的资源。应优先改善 HPV 和 HBV 疫苗接种的实施并提高其覆盖率,以减轻这一负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medical Economics
Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL
CiteScore
4.50
自引率
4.20%
发文量
122
期刊介绍: Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信